Key highlights

  • Goodman Group (ASX:GMG) is targeting FY27 operating earnings per security growth of 9%, with data centres 78% of its development work in progress.
  • Pro Medicus (ASX:PME) said implementations will provide a step-up in FY27 from a full 12 months of revenue.
  • ResMed (ASX:RMD) expects to return more than US$1.85 billion to shareholders in FY2027 and raised its quarterly dividend by 10%.

Data centre developers, medical imaging software providers and sleep therapy device makers reported results linked to technology and healthcare demand. This article reviews the forward-looking commentary of Goodman Group (ASX:GMG), Pro Medicus Limited (ASX:PME) and ResMed Inc. (ASX:RMD), based on their latest announcements.

The theme is what lies ahead: Goodman’s development pipeline, Pro Medicus’ contract implementations and ResMed’s capital return plans.

Goodman Group (ASX:GMG)

Goodman reported FY26 operating profit of $2,674.5 million, up 15.7%, operating earnings per security of 129.9 cents, up 10.1%, and a portfolio of $89.0 billion with occupancy of 95.6%. Gearing was 6.5%.

Its forward position rests on development: work in progress was $19.7 billion across 50 projects in 12 countries, 78% of it data centres, with a forecast yield on cost of 8.2%, and a global power bank of 6.4 GW across 16 major cities. The group is targeting FY27 operating earnings per security growth of 9%.

Pro Medicus Limited (ASX:PME)

In an interview about its full-year results, Pro Medicus said NPAT grew more than 32% in constant currency and that it had its second-biggest year for new contracts, six major renewals and its busiest year for implementations. Currency translation reduced revenue by just under $12 million and NPAT by $9.8 million.

The company said implementations did not contribute materially to FY26 revenue but will provide a step-up in FY27 from a full 12 months of revenue. It also discussed AI and cardiology, and referred to $10 million investments in 4D Medical and Echo IQ.

ResMed Inc. (ASX:RMD)

ResMed reported fiscal 2026 revenue of US$5.7 billion, up 10%, non-GAAP diluted EPS of US$11.17, up 17%, operating cash flow of US$1.8 billion and free cash flow of US$1.6 billion. Fourth-quarter revenue rose 9% to a record US$1.5 billion.

For fiscal 2027, ResMed guided to more than US$1.85 billion returned to shareholders through repurchases and dividends and announced a 10% increase in its quarterly dividend to US$0.66. It also agreed to sell its MatrixCare business and completed the acquisition of Noctrix Health.

General risks to keep in mind

Property developers and data centre builders depend on customer demand for space and power, planning approvals, construction costs and funding conditions. Software providers with contracts that take time to implement can see revenue timing move, and currency translation affects companies that earn overseas income. Medical device makers face reimbursement, regulatory and competitive influences. Outlook statements assume stable conditions and may change.

What investors might be watching

  • Goodman’s conversion of its power bank and work in progress into completed projects, and its FY27 earnings per security target.
  • Pro Medicus’ implementations and the timing of revenue from them in FY27.
  • ResMed’s share repurchases, dividend payments and integration of Noctrix Health.
  • Demand for data centre capacity and the availability of power.
  • Exchange rate effects on the earnings of both Pro Medicus and ResMed.

The next phase for the three companies

Goodman has set a FY27 growth target and a large development pipeline, Pro Medicus is waiting for implementations to feed through to revenue, and ResMed has set out capital returns and portfolio changes. The next results will show how each plan is progressing.